Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 projectwaystar-2q26earning.htm EX-99.1 Document Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth President & Chief Operating Officer Ryan Cohlhepp, Pharm.D.
EX-99.1 2 projectwaystar-2q26earning.htm EX-99.1 Document Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board of Directors and serve as Strategic Advisor On track for substantial enrollment of pivotal FORTIFI-HN01 study by year-end, enabling topline results from interim analysis in mid-2027; initiated FORTIFI-FLEX alternate dosing study Company to host conference call and webcast today, Tuesday, August 11, 2026 at 8:30 am ET BOSTON, August 11, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patient...
Source
Exhibit EX-99.1
0001628280-26-055500
Filed August 11, 2026 at 11:36 AM UTC. The figures above are from the audited statements, not from this release.